Navigation Links
New data on hormone therapy must lead to re-evaluation of official guidelines
Date:10/18/2007

As opinion leaders in the field of menopause medicine from various areas in the world, we wish to emphasize the following points concerning postmenopausal hormone therapy:

  1. Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms and estrogen-deficient urogenital symptoms.

  2. The initial interpretation of the Womens Health Initiative (WHI) trial failed to recognize the immense importance of age and years since menopause on outcomes of HT. The potential impact of specific hormonal regimens on safety of HT should be considered as well.

  3. The results of the WHI trial were wrongly extrapolated to the whole postmenopausal population, which led to a major change in recommendations and guidelines on HT.

  4. Based on current knowledge, the balance between the benefits and risks of HT is clearly in favor of use in the early postmenopausal years for symptomatic, healthy women.

  5. All previous studies, including the WHI trial, have demonstrated significant positive effect on bone density and reduction in fracture risk among hormone users.

  6. Estrogen has favorable metabolic and cardioprotective effects in healthy, young postmenopausal women. The results for the age group 5059 years in the WHI estrogen-alone arm support this claim. Estrogen slows the pace of development of atherosclerosis if started in the early postmenopausal period.

  7. HT may be associated with a small increase in risk for breast cancer, if taken long term. Combined estrogenprogestogen therapy probably carries a higher risk than that recorded for estrogen alone. Prevalence of stroke and thromboembolism strongly correlates with age; therefore, the impact of the HT-related increased risk in this respect becomes more important in the late menopause. Low-dose estrogen or the transdermal route of administration may lead to a more favorable risk profile.

  8. Progestins, combined with estrogen, may decrease the magnitude of estrogen-related cardiac benefits, and increase the risk for breast cancer. There are insufficient data to evaluate the possible differences in the incidence of breast cancer using different types and routes of progestin administration.

Based on the above, we call upon the health authorities to review their policies and revise them in view of the new age-related data on HT. Also, the different outcomes of estrogen-alone and estrogen plus progestin therapy should be considered. Overall, the safety profile of HT until age 60 is favorable, and should not preclude women from using HT when appropriate. Issues of quality of life, including mental, emotional, cognitive and sexual function, should have a higher priority while discussing regulatory policies and official guidelines on postmenopausal HT use.


'/>"/>

Contact: Jean Wright
jwright.ims@btopenworld.com
International Menopause Society
Source:Eurekalert

Related medicine news :

1. Thyroid hormone treatment hastens recovery after cardiac surgery
2. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
3. Hormone replacement Therapy a headache
4. Ovarian cancer in relationship with Hormone therapy
5. Evaluating The Risks and Benefits of Hormone Therapy
6. Scientists crack mechanism of Leptin-Obesity Hormone
7. Scientists use plant hormones to fight cancer
8. Use parathyroid hormone to fight brittle bone disease
9. Multiple Sclerosis Can Be Treated By Blocking Fat Hormone
10. Hormone contraceptives lead to bone problems
11. Hormone treatment helps obese people slim down
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... The CFOs included on this ... systems in the nation and help their organizations navigate the challenges in healthcare ... instrumental in developing successful hospital and health system strategy. , Becker's Hospital Review ...
(Date:5/23/2017)... CLARA, CA (PRWEB) , ... May 23, 2017 , ... ... and financial organizations, today announced CIO Applications magazine has named the company a ... its innovative use of the Cloud to help organizations simply and proactively address potential ...
(Date:5/23/2017)... Santa Rosa, California (PRWEB) , ... May 23, ... ... population health management (PHM) technology and a 2017 Best in KLAS category winner, ... an advantageous market position to extend and enhance its technology platform and product ...
(Date:5/23/2017)... ... 23, 2017 , ... Drs. Allen Huang and Jeffrey Wang, ... Las Vegas, NV, and the importance of treating it immediately. They are now ... for peri-implantitis, with or without a referral. As experienced periodontists and implant specialists, ...
(Date:5/23/2017)... San Diego, CA (PRWEB) , ... May 23, 2017 , ... ... including bleeding gums and chronic bad breath, can now receive laser gum disease treatments ... Addleson, R. Douglas Campbell and David Landau are raising awareness of the importance of ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... SAN DIEGO , May 4, 2017 /PRNewswire/ ... is demonstrating its wireless, handheld ultrasound scanners this ... Gynecologists Annual Scientific Meeting (ACOG) in ... 2017. "Clarius is the perfect ... fetal growth and heart rate, and evaluate pregnancy-related ...
(Date:5/4/2017)...  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... today announced that it is teaming up with Auto ... to lower diabetes healthcare costs in Canada ... is available throughout all provinces and territories in ... for additional savings when shopping for Dario supplies in ...
(Date:5/4/2017)... 4, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... "Company"), today announced that the Company,s first quarter 2017 ... Thursday, May 11, 2017, and that the Company will ... p.m. PT that afternoon. Management will provide an overview ...
Breaking Medicine Technology: